Inmune Bio Reports Statistically Significant Positive Phase 2 Alzheimer's Trial Results for XPro1595
INMB sits 30% above its 52-week low of $1.09 on elevated volume (2.4× avg).
Summary
Inmune Bio announced statistically significant positive results from its Phase 2 MINDFuL trial for XPro1595 in early Alzheimer's disease, demonstrating a treatment effect on white matter biomarkers.
Key Events · Product Development and Regulatory · INMB
-
Positive Phase 2 Clinical Trial Results
XPro1595 showed a statistically significant treatment effect on myelin in the full mITT population (p=0.0028) of the MINDFuL Phase 2 trial for early Alzheimer's disease.
-
Validation of Precision Medicine Approach
Efficacy was further strengthened in biomarker-enriched patients with elevated inflammation (p=0.0098), validating the company's precision-medicine strategy for its Phase 2b/3 registrational program.
-
De-risked Regulatory Pathway
The positive results follow FDA Fast Track designation and End-of-Phase 2 alignment for an integrated Phase 2b/3 seamless adaptive trial, providing a clear path toward commercial submission.
-
Addresses Going Concern Warning
This critical positive data provides a strong scientific foundation for continued development and potential future financing, directly addressing the company's previously disclosed 'going concern' warning.
Analysis · INMB · Life Sciences
This filing announces statistically significant positive results from the Phase 2 MINDFuL clinical trial of XPro1595 in early Alzheimer's disease. The data, showing a treatment effect on white matter biomarkers, is critical for Inmune Bio, especially given its recent 'going concern' warning. Positive clinical data provides a strong scientific foundation for continued development and is essential for attracting future financing, directly addressing the company's liquidity concerns and de-risking its path forward. The FDA Fast Track designation and regulatory alignment for a seamless Phase 2b/3 registrational program further enhance the significance of these results.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 41.9% of the 327 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INMB was trading at $1.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $37.8M. The 52-week trading range was $1.09 to $11.64. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.